Bristol Myers Squibb (BMY.US) and Bain Capital join hands to establish a new biopharmaceutical company to develop therapies for autoimmune diseases.

According to the Finance and Economics APP, Bristol Myers Squibb (BMY.US) and Bain Capital jointly announced that they will establish a new independent biopharmaceutical company focusing on the research and development of therapies for autoimmune diseases.